CINÉTICA DE LOS ANTICUERPOS IgG E IgM ANTI-CITOMEGALOVIRUS DESPUÉS DEL NACIMIENTO
Resumen
En el presente estudio se estudió la cinética de los anticuerpos IgM e IgGanticitomegalovirus en suero de niños menores de un año que han nacidoy hacen sus controles en el Hospital Santa María de Cutervo, Cajamarca,del periodo 2015-2016. El estudio se realizará con muestras de suero de480 niños, las cuales serán procesados por la técnica de ELISA para la determinación de IgM e IgG específicas anti-citomegalovirus (anti-CMG). Enresultados previos obtenidos en 70 muestras de donantes se encontró, queel 54 % (38) fueron donantes femeninos, ninguno reactivo a IgM anti-CMVy 95 % (36) reactivo a IgG anti-CMV. El 46 % (32) fueron donantes masculinos,ninguno reactivo a IgM anti-CMV y todos reactivos a IgG anti-CMV.Se determinó en el estudio previo de donantes de sangre que ninguno deellos tiene infección reciente causada por citomegalovirus (como lo muestraIgM anti-CMV) pero un alto porcentaje (97 %) resultó reactivo para IgGanti-CMV.Descargas
Citas
Adjei, A.A.; Armah, H.B.; Narter-Olaga, E.G. 2006. Seroprevalence of Cytomegalovirus among some voluntary blood donors at the 37 Military Hospital, Accra, Ghana. Ghana Medicine Journal, 40: 99-104.
Adler, S.P. 1983. Transfusion-associated cytomegalovirus infections. Reviews of Infectious Diseases, 5: 977-993.
Alford, C.A.; Stagno, S.; Pass, R.F. & Britt, W.J. 1990. Congenital and perinatal cytomegalovirus infections. Reviews of Infectious Diseases, 12: 745-753.
Amy, J.; Clippinger, T.G.; Maguire, T & Alwine, J.C. 2011. Human Cytomegalovirus infection perinuclear localization during amino acid maintains mTOR activity and its deprivation. Journal of Virology, 85: 93699376.
Bate, S. L; Dollard, S. C. & Cannon, M. J. 2010. Cytomegalovirus sero prevale nee in the United States: The national health and nutrition examination surveys 1988- 2004. Infectious Diseases Society of America, 50, 1439-1447.
Benmarzouk-Hidalgo, O. J.; Cisneros, J. M.; Cordero, E.; Martín-Peña, A.; Sanchez, B.; Martin-Gandul, C.¡Gentil, M. A.; Gómez-Bravo, M. A.; Lage, E. & PérezRomero, P. 2011.
Therapeutic effect of the acquisition of cytomegalovirus-specific immune response during preemptive treatment. Antimicrobial Agents Chemotherapy, 91,927-933.
Berardi, A.; Rossi, C.¡ Fiorini, V.; Rivi, C.¡ Vagnarelli, F.¡ Guaraldi, N.; Pietrosemoli, P.; Lazzarotto, T. & Ferrari, F. 2011. Severe acquired cytomegalovirus infection in a full- term, formula-fed infant: case report, BMC Pediatrics, 6, 52.
Boeckh, M. Geballe, A. P. 2011. Cytomegalovirus: pathogen, paradigm, and puzzle. The Journal Clinical Investigation, 121,1673-1680.
Bowden, R. A.; Sayers, M.; Flournoy, N.; New-ton, B.; Banaji, M.; Thomas, E. D. & Meyers, J.D. 1986. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. The New England Journal
of Medicine, 314, 1006-1010.
Bowden, R. A.; Slichter, S. J.; Sayers, M.; Weis-dorf, D.; Cays, M.; Schock, G.; Banaji, M.; Haake, R.; Welk, K.; Fisher, L. & McCullough, J. 1995. A comparison of leukocytereduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfus ion-associated CMV infection after marrow trans-plant. Blood, 86, 3598-3603.
Bueno, J.; Ramil, C. & Green, M. 2002. Current management strategies for the prevention and treatment of cytomegalovirus infection in pediatric transplant recipients. Paediatrics Drugs, 4(5), 279-90.
Cannon, M. J.; Schmid, D. S. & Hyde T. B. 2010. Review of cytomegalovirus sero prevale nee and demographic characteristics associated with infection. Review in Medical Virology, 20, 202-13.
Chilet, M.; Aguilar, T.; Benet, I.; Belda, J.; Tormo, N.¡ Carbonell, J. A.; Clari, M. A.; Costa, E. & D. Navarro. 2010. Virological and immunological features of active cytomegalovirus infection in nonimmunosuppressed patients in a surgical and trauma intensive care unit.
Journal of medical virology, 82, 1384-91.
Colugnati, F. A.; Staras, S. A.; Dollard, S. C. & Cannon, M. J. 2007. Incidence of cytomegalovirus infection among the general population and pregnant women in the United States. BMC infectious diseases, 2, 70:71
de Jong, M. D.; Galasso, G. J.; Gazzard, B.; Griffiths, P. D.; Jabs, D. A.; Kern, E. R. & SpectorS. A. 1998. Summary of the II International Symposium on Cytomegalovirus. Antiviral research, 39, 141-162.
Drebber, U.; Hardt, A.; Dienes, H. P. & Odenthal, M. 2011. ol¡ytomegalovirus. Pathologicalanatomical
manifestations and detection methods. Der Pathologe, 32, 418-27.
Drew, W. L; Tegtmeier, G.; Alter, H. J.; Laycock, M. E.; Miner, R. C. & Busch M. P. 2003.
Frequency and duration of plasma CMV viremia in sero-converting blood donors and recipients. Transfusion, 43, 309-313.
Gargouri, J.; Elleuch, H.; Karray, H.; Rekik, H. & Hammami, A. 2000. Prevalence of anti-CMV antibodies in blood donors in the Sfax region (value in blood transfusion). Médicale La Tunisie, 78, 512-517.
Gilbert, G. L.; Hayes, K.; Hudson, I. L. & James, J. 1989. Prevention of transfusionacquired cytomegalovirus infection in infants by blood filtration to remove leucocytes. Neonatal Cytomegalovirus Infection Study Group. The Lancet, 1, 1228- 1231.
Griffiths, P. D. 2002. Strategies to prevent CMV infection in the neonate. Seminars in neonatology, 7, 293-299.
Luis Emilio Carranza Quispe Gutiérrez-Salinas, J.; Carmona-García, R.; García-Ortiz, L.; Chima-Galán, M. C.; Suástegui-Domínguez, S.; Espinosa-Elizondo, R. M.; Treviño-Mejia, A. J.; Garcia- Méndez,
S. & Rivera-Badillo, M. E. 2010. Detección de infección asintomática por citomegalovirus en donadores voluntarios de sangre. Medicina Interna de México, 26, 109-115.
High, K. P. 2005. Chronic infection and frailty: surrogate markers, associations, and causality. Journal of the American Geriatrics Society, 53, 906-908. Holland, P. V. & Schmitt, P. J. 1987. Standards for blood banks and transfusion services: Arlington VA: Committee on standards. American Association of Blood Banks, 30-31.
Jim, W. T; Shu, C. H.; Chiu, N. C.; Chang, J. H.; Hung, H. Y.; Peng, C. C.¡ Kao, H. A.; Wei, T. Y.; Chiang, C. L. & Huang, F. Y 2009. High cytomegalovirus load and prolonged virus excretion in breast milk increase risk for viral acquisition by very low birth weight infants.
The Pediatric infectious disease journal, 28, 891 -894.
Jutte, J. C.; Wessels, E.; Anna, M. H.; Annemiek, A.; Vander, E.; Lisette, G.; Aloys, C. M. & Ann, C. T. 2012. Rapid Genotyping of Cytomegalovirus in Dried Blood Spots by Multiplex Real-Time PCR Assays Targeting the Envelope Glycoprotein gB and gH Genes. Journal of Clinical Microbiology, 50, 232.
Kothari, A.¡ Ramachandran, V. G.; Gupta, P.; Singh, B. & Talwar V. 2002. Sero prevale nee of cytomegalovirus among voluntary blood donors in Delhi, India. Journal of health, population, and nutrition, 20, 348-351.
Krajden, M.; Shankaran, P.; Bourke, C. & Lau, W. 1996. Detection of cytomegalovirus in blood donors by PCR using the digene SHARP signal system assay: effects of sample preparation and detection methodology.
Journal of Clinical Microbiology, 34, 29-33.
Kraat, Y. J., R. M. Hendrix, M. P. Landini, and C. A. Bruggeman. 1992. Comparison of four techniques for detection of antibodies to cytomegalovirus, Journal Clinic of Microbiology, 30, 522-524.
Luck, S. Sharland, M. 2009. Postnatal cytomegalovirus: innocent bystander or hidden problem?. Archives of disease in childhood. Fetal and neonatal edition. 94, 58-64. Miller, W. J.; McCullough, J.; Balfour, H.; Haake, R. J.; Ramsay N. K.; Goldman, A.; Bowman, R.
& Kersey, J. 1991. Prevention of cytomegalovirus infection following bone marrow transplantations: a randomized trial of blood product screening.
Bone Marrow Transplant, 7, 227-234.
Narvios, A. B. & Lichtiger, B. 2001. Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: a retrospective study. Haematologica, 86, 952.
Nichols, W. G.; Price, T. H.; Gooley, T.; Corey, L. & Boeckh, M. 2003. Transfusion transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood, 101,4195-4200.
Osawa, R. & Singh, N. 2009. Cytomegalovirus infection in critically ill patients: a systematic review. Critical Care, 13, 68.
Schmaltz, H. N.; Fried, L. P.; Xue, Q-L.; Walston, J.; Leng, S. X. & Semba, R. D. 2005. Chronic cytomegalovirus infection and inflammation are associated with prevalent, frailty in community dwelling older women. Journal of the American Geriatrics Society, 53, 747-754.
Sóderberg Naucler-C. 2006. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer?. Journal of Internal Medicine, 259, 219-246.
Staras, S. A.; Dollard, S. C.; Radford, K. W.; Flanders, W. D.; Pass, R. F. & Cannon, M. J. 2006. Seroprevalence of cytomegalovirus infection in the United States 1988-1994. Clinical Infectious Diseases, 43, 1143-1151.
Tegtmeier, G. E. 1989. Posttransfusion cytomegalovirus infections. Archives of Pathology & Laboratory Medicine, 113, 236-45.
Thiele, T.; Krüger, K.;, Zimmermann, K.; Ittermann, T.; Wessel, A.; Steinmetz, I.; Dolken, T. & Greinacher, A. 2011. Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a singlecenter prospective study in
high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME). Transfusion, 51,2620-2626.
Trincado, D. & Rawlinson, W. D. 2001. Congenital and perinatal infections with cytomegalovirus. Journal of Paediatrics and Child Health, 37, 187-192. Wu, C. A.; Paveglio, S. A.; Lingenheld, E. G.; Zhu, L.; Lefrangois, L. & Lynn, P. 2011. Transmission of Murine Cytomegalovirus in Breast Milk: a Model of Natural Infection in Neonates. Journal of Virology, 85, 5115-5124.
Yeager, A. S. Grumet, F.C.; Hafleigh, E. B.; Arvin, A. M.; Bradley, J. S. & Prober, C. G. 1981. Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. Journal of Pediatrics, 98, 281-287.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
CC BY-NC-SA : Esta licencia permite a los reutilizadores distribuir, remezclar, adaptar y construir sobre el material en cualquier medio o formato solo con fines no comerciales, y solo siempre y cuando se dé la atribución al creador. Si remezcla, adapta o construye sobre el material, debe licenciar el material modificado bajo términos idénticos.
OAI-PMH URL: https://revista.uniandes.edu.ec/ojs/index.php/METANOIA/oai
